New Alzheimer’s drug rejected by NICE
Despite setbacks, the quest for groundbreaking Alzheimer’s treatments continue.
A future with decentralised science
Promoting equity and transparency in scientific research and healthcare data storage.
ICLR celebrate EuRoC success
Felix sits down with ICLR members Andrei Paduraru, Soham More and Pablo Duhamel to discuss the trials and triumphs of launching Nimbus 24
AI to Z: The paradigmatic shift facing the world as we know it
Examining the impacts of AI from industry to intelligence.
Hopfield and Hinton awarded Nobel Prize for shaping the neural network landscape
John Hopfield and Geoffrey Hinton are recognised for their seminal work in artificial neural networks and machine learning.
The tiny molecule that answers a big question
The discovery of microRNA was finally acknowledged in this year’s Nobel Prize in medicine.
Understanding the shape of life
The 2024 Nobel Prize in chemistry was awarded to David Baker, Demis Hassabis, and John Jumper for their protein structure breakthroughs.
Felix interviews Prof Claudia de Rham
Imperial physicist and author sits down with Felix to discuss all things gravity and her life in academia.
Welcome to Felix Science
The team wishes all students and staff members a warm welcome back to Imperial for the brand new academic year.
The insulin controversy in the US: a financial tug-of-war
On the rising prices of insulin in the US and the impact on both companies and patients.
Imperial student develops flat-pack homes for earthquake-stricken regions
MEng student Mayar Ariss’ design aims to reduce the impact of humanitarian crises worldwide.
AstraZeneca COVID vaccine: boon or bane?
Last month, AstraZeneca announced that they are withdrawing the vaccine from the market. The company said “as multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines. This has led to a decline in demand for our vaccine, which is no longer being manufactured